GT Biopharma (GTBP) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 15, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-40023
Entity Registrant Name	GT BIOPHARMA, INC.
Entity Central Index Key	0000109657
Entity Tax Identification Number	94-1620407
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	8000 Marina Blvd
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	415
Local Phone Number	919-4040
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	GTBP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,434,944

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 2,045	$ 5,672
Short-term investments	17,854	10,836
Prepaid expenses and other current assets	38	54
Total Current Assets	19,937	16,562
Operating lease right-of-use asset	140	165
Deposits	9	9
TOTAL ASSETS	20,086	16,736
Current liabilities
Accounts payable	3,131	3,140
Accrued expenses	829	1,669
Current operating lease liability	116	110
Total Current Liabilities	4,076	4,919
Non-current operating lease liability	31	64
Warrant liability	2,926	19
Total Liabilities	7,033	5,002
Stockholders’ Equity
Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	1	1
Common stock, par value $0.001, 750,000,000 shares authorized, 36,303,218 shares and 32,061,989 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	37	33
Additional paid in capital	687,710	686,168
Accumulated deficit	(674,695)	(674,468)
Total Stockholders’ Equity	13,053	11,734
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 20,086	$ 16,736

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	15,000,000	15,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	36,882,724	32,722,452
Common stock, shares outstanding	36,882,724	32,722,452
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	96,230	96,230
Preferred stock, shares outstanding	96,230	96,230

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenues
Operating Expenses:
Research and development	1,650,000	2,087,000
Selling, general and administrative (including $718 and $447 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2023 and 2022, respectively)	2,015,000	3,355,000
Loss from Operations	3,665,000	5,442,000
Other (Income) Expense
Interest income	(164,000)	(8,000)
Interest expense	212,000
Change in fair value of warrant liability	(2,924,000)	(18,000)
Gain on extinguishment of debt	(533,000)
Unrealized (gain) loss on marketable securities	(29,000)	24,000
Total Other (Income) Expense	(3,438,000)	(2,000)
Net Loss	$ (227,000)	$ (5,440,000)
Net Loss Per Share - Basic and Diluted	$ (0.01)	$ (0.17)
Weighted average common shares outstanding - basic and diluted	39,085,515	32,486,116

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Selling, General and Administrative Expenses [Member] | Officers Employees and Directors [Member]
Share-based payment arrangement, expense	$ 718	$ 447

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total	Common Shares Issuable [Member]
Beginning balance, value at Dec. 31, 2021	$ 1,000	$ 32,000	$ 674,348,000	$ (653,584,000)	$ 21,910,000	$ 1,113,000
Beginning balance, shares at Dec. 31, 2021	96	32,062				327
Equity compensation to officers, employees, and board of directors			447,000		447,000
Equity compensation to officers, employees, and board of directors, shares		85
Issuance of common shares for services			872,000		872,000
Issuance of common stock for services, shares		163
Net loss				(5,440,000)	(5,440,000)
Cancellation of common stock previously issued for services
Cancellation of common stock previously issued for services, shares		(291)
Common shares issued upon conversion of notes payable			1,113,000			$ (1,113,000)
Common stock issued upon conversion of notes payable, shares		327				(327)
Ending balance, value at Mar. 31, 2022	$ 1,000	$ 32,000	676,780,000	(659,024,000)	17,789,000
Ending balance, shares at Mar. 31, 2022	96	32,346
Beginning balance, value at Dec. 31, 2022	$ 1,000	$ 33,000	686,168,000	(674,468,000)	11,734,000
Beginning balance, shares at Dec. 31, 2022	96	32,723
Private placement of common stock		$ 4,000	6,264,000		6,268,000
Beginning balance, shares		3,600
Initial recognition of fair value of warrant liability			(5,831,000)		(5,831,000)
Equity compensation to officers, employees, and board of directors			507,000		507,000
Equity compensation to officers, employees, and board of directors, shares
Issuance of common shares for services			315,000		315,000
Issuance of common stock for services, shares		73
Issuance of common shares in settlement of vendors payable			287,000		287,000
Beginning balance, shares		487
Net loss				(227,000)	(227,000)
Ending balance, value at Mar. 31, 2023	$ 1,000	$ 37,000	$ 687,710,000	$ (674,695,000)	$ 13,053,000
Ending balance, shares at Mar. 31, 2023	96	36,883

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (227,000)	$ (5,440,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation - services	176,000	872,000
Stock based compensation - officers, employees and board of directors	646,000	447,000
Change in fair value of warrant liability	(2,924,000)	(18,000)
Gain on extinguishment of shares settled debt	(533,000)
Change in operating lease right-of-use assets	25,000	23,000
Unrealized (gain) loss on marketable securities	(29,000)	24,000
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses	16,000	(263,000)
(Increase) in deposits		(9,000)
Decrease in accounts payable and accrued expenses	(29,000)	(838,000)
Decrease in operating lease liability	(27,000)	(13,000)
Net Cash Used in Operating Activities	(2,906,000)	(5,215,000)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(6,989,000)
Sale of investments		3,533,000
Net Cash Provided by (Used in) Investing Activities	(6,989,000)	3,533,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and prefunded warrants	6,268,000
Net Cash Provided by Financing Activities	6,268,000
Net (Decrease) in Cash	(3,627,000)	(1,682,000)
Cash at Beginning of Period	5,672,000	8,968,000	$ 8,968,000
Cash at End of Period	2,045,000	7,286,000	$ 5,672,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest
Income taxes paid
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Right-of-use assets and lease liabilities recognized pursuant to lease agreement		260,000
Initial recognition of fair value of warrant liability	5,831,000
Fair value of common stock issued to a vendor to settle accounts payable	$ 287,000

Organization and Operations

Organization and Operations	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 – Organization and Operations In 1965, the corporate predecessor of GT Biopharma Inc. (Company), Diagnostic Data, Inc. was incorporated in the State of California. Diagnostic Data changed its incorporation to the State of Delaware in 1972 and changed its name to DDI Pharmaceuticals, Inc. in 1985. In 1994, DDI Pharmaceuticals merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. In July 2017, the Company changed its name to GT Biopharma, Inc. The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The Company’s TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (NK cells).

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 30, 2023 (the “2022 Annual Report”). The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. Liquidity The accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2023, the Company recorded a net loss of $ 227,000 , and used cash in operations of $ 2.9 million. As of March 31, 2023, the Company had a cash and short-term investments balance of $ 19.9 million, working capital of $ 15.9 million and stockholders’ equity of $ 13.1 million. Management anticipates that the $ 19.9 million of cash and cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the date the Company’s condensed consolidated financial statements for the three months ended March 31, 2023 were issued. Historically, the Company has financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs or ability to continue operations. COVID-19 The global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma’s operations and business plan. The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic’s future impact on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom GT Biopharma does business. Accounting Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those estimates. Cash Equivalents and Short-Term Investments The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to approximately $ 1.8 5.5 The Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying condensed consolidated statements of operations. Total short-term investments amounted to approximately $ 17.9 10.8 Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The three levels of the fair value hierarchy are as follows: Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amount of the Company’s warrant liability of $ 2.9 19,000 The carrying amounts of the Company’s other financial assets and liabilities, such as cash, other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments. Derivatives and Liability-Classified Instruments The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the guidance provided by the Financial Accounting Standards Board in ASC 480 , Distinguishing Liabilities from Equity (ASC 480) Derivatives and Hedging (ASC 815) Stock-Based Compensation The Company accounts for share-based awards to employees, non-employees and consultants in accordance with the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense over the requisite service, or vesting period. Research and Development Costs Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Leases The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments, see Note 7 – Operating Leases for the Company’s lease disclosures. Net Loss Per Share Basic loss per share is computed using the weighted-average number of common shares outstanding during the period. Common stock issuable is included in our calculation as of the date of the underlying agreement. Diluted loss per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable for the exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Pre-funded warrants are treated as stock equivalents for purposes of calculating net loss per share. These following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities   March 31, 2023 (Unaudited)   March 31, 2022 (Unaudited)   Options to purchase common stock 3,467,915 302,500 Warrants to purchase common stock 9,148,880 2,337,274 Unvested restricted common stock - 681,270 Total anti-dilutive securities  12,616,795   3,321,044  Concentration Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $ 250,000 The Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4– Accounts Payable for further information. Segments The Company determined its reporting units in accordance with ASC 280, “Segment Reporting” (“ASC 280”). Management evaluates a reporting unit by first identifying its’ operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated. Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (the “SEC”) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments The estimated fair values of financial instruments outstanding were (in thousands): Schedule of Estimated Fair Value of Financial Instrument March 31, 2023 (Unaudited) Unrealized Unrealized Fair Cost Gains Losses Value Short-term investments $ 17,883 $ — $ (29 ) $ 17,854 Total $ 17,883 $ — $ (29 ) $ 17,854 December 31, 2022 Unrealized Unrealized Fair Cost Gains Losses Value Short-term investments $ 10,866 $ — $ (30 ) $ 10,836 Total $ 10,866 $ — $ (30 ) $ 10,836 The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): Schedule of Fair Value Hierarchy Financial Assets Fair Value Level 1 Level 2 Level 3 March 31, 2023 (Unaudited) Fair Value Level 1 Level 2 Level 3 Money market funds $ 1,837 $ 1,837 $ — $ — Corporate notes and commercial paper 17,854 17,854 — — Total financial assets $ 19,691 $ 19,691 $ — $ — 1 2 3 4 December 31, 2022 Fair Value Level 1 Level 2 Level 3 Money market funds $ 5,505 $ 5,505 $ — $ — Corporate notes and commercial paper 10,836 10,836 — — Total financial assets $ 16,341 $ 16,341 $ — $ — As of March 31, 2023, the fair value of the warrant liability was $ 2.9 Schedule of Derivative Liability Transactions   March 31, 2023 March 31, 2022   Three Months Ending   March 31, 2023 March 31, 2022   (Unaudited) (Unaudited) Beginning balance $ 19 $ 138 Issuance of warrants at fair value 5,831 — Change in fair value (2,924 ) (18 ) Extinguishment — — Ending balance $ 2,926 $ 120

Accounts Payable

Accounts Payable	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accounts Payable	Note 4 – Accounts Payable Accounts payable consisted of the following (in thousands): Schedule of Accounts Payable March 31, 2023 (Unaudited) December 31, 2022 Accounts payable to a third-party manufacturer $ 2,114 $ 2,283 Other accounts payable 1,017 857 Total accounts payable $ 3,131 $ 3,140 The Company relies on a third-party contract manufacturing operation to produce and/or test our compounds used in our potential product candidates. In October 2020, the Company entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently executed a number of Statements of Work for the research and development of products for use in clinical trials. On August 24, 2022, existing agreements with the third-party product manufacturer were amended. As part of the amendment, the third-party manufacturer agreed that services to be rendered in future periods, will be paid or settled at the Company’s discretion, in a combination of cash and issuance of the Company’s common stock. The amendment also eliminated future financial commitments of the Company. As of December 31, 2022, outstanding accounts payable balance to the third-party product manufacturer amounted to $ 2.3 During the period ended March 31, 2023, the Company recorded research and development expenses of $ 1.3 million to account for services rendered by the 600,000 486,819 287,000 820,000 533,000 2.1

Warrant Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2023
Warrant Liability
Warrant Liability	Note 5 – Warrant Liability 2023 Warrants On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of 6,500,000 shares of the Company’s common stock (the “Common Warrants”), and placement agent warrants to purchase up to 390,000 of the Company’s common stock (the “Placement Agents Warrants”) see Note 6 - Stockholders’ Equity. The Common Warrants provide for a value calculation for the Common Warrants using the Black- Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at 100 5.8 2.9 All changes in the fair value of the warrant liabilities are recognized as a change in fair value of warrant liability in the Company’s condensed consolidated statements of operations until they are either exercised or expire. The warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following assumptions: Schedule of Derivative Liabilities Assumptions (Unaudited) (Unaudited)   Common Warrants and Placement Agents Warrants   At Inception March 31, 2023 (Unaudited) (Unaudited) Stock price $ 1.02 $ 0.55 Risk-free interest rate 3.60 % 3.60 % Expected volatility        121.5%        120.4% Expected average life (in years) 5.0 4.76 Expected dividend yield - - Fair value of warrants (in thousands) $ 5,831 $ 2,919 2020 Warrants During the year ended December 31, 2020, the Company issued certain warrants that contained a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of these warrants is classified as a liability in the Condensed Consolidated Balance Sheets and will be re-measured at the end of every reporting period with the change in value reported in the Condensed Consolidated Statements of Operations. The warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions: Schedule of Derivative Liabilities Assumptions March 31, December 31, 2023 2022 (Unaudited) Stock price $ 0.55 $ 0.89 Risk-free interest rate 4.06 % 4.22 % Expected volatility 106.6 % 109 % Expected life (in years) 2.3 2.6 Expected dividend yield - - Fair value of warrants (in thousands) $ 7,000 $ 19,000 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the derivative securities was determined by the remaining contractual life of the derivative instrument. For derivative instruments that already matured, the Company used the estimated life. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. The Company recognized a gain of $ 2.9 18,000

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Equity	Note 6 – Stockholders’ Equity The Company’s authorized capital as of March 31,2023 was 250,000,000 0.001 15,000,000 0.01 Common Stock Private Placement of Common Stock On January 4, 2023, GT Biopharma received gross proceeds of $ 6.5 million, before deducting placement agent fees and other offering expenses of $ 232,000 in relation to a purchase agreement (the “Purchase Agreement”) signed on December 30, 2022, between the Company and an institutional investor (the “Purchaser”) for the issuance and sale, in a registered direct offering (the “Offering”), of 3,600,000 shares of the Company’s common stock, par value $ 0.001 per share (the “Shares”), pre-funded warrants to purchase up to 2,900,000 shares of the Company’s common stock (the “Pre-Funded Warrants”), warrants to purchase up to an aggregate of 6,500,000 shares of the Company’s common stock (the “Common Warrants”) and placement agent warrants to purchase up to 390,000 shares of the Company’s common stock (the “Placement Agents Warrants”). The Common Warrants have an exercise price equal to $ 1.00 , will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercisable date. The Pre-Funded Warrants have an exercise price of $ 0.0001 per Share, are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. The Placement Agents Warrants have an exercise price equal to $ 1.25 , will be exercisable commencing six months following issuance, and will have a term of exercise equal to five years following the initial exercisable date. The Common Warrants and the Placement Agents Warrants contained a clause not considered to be within the Company’s control. The Company determined that the provision represented a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under ASC 815-40, and thus the Common Warrants and the Placement Agent Warrants are not considered indexed to the Company’s own stock and not eligible for an exception from derivative accounting. Accordingly, the Common Warrants and the Placement Agent Warrants were classified as a warrant liability, and $ 5.8 Common Stock Issuable On February 16, 2021, because of the mandatory conversion of the notes payable and accrued interest in the aggregate amount of $ 38.8 11,413,322 11,086,024 327,298 1.1 Cancellation of common stock The Company cancelled 290,999 Common stock issued for services During the three months ended March 31, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued 73,454 315,000 247,429 1.3 Common stock issued for vendor payable On March 13, 2023, the Company issued 486,819 287,000 820,000 533,000 Preferred Stock Series C Preferred Stock At March 31, 2023 and December 31, 2022, there were 96,230 0.01 As a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the 96,230 Series K Preferred Stock On February 16, 2021, the Board designated 115,000 .01 Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company’s common stock at an effective conversion rate of 100 As of March 31, 2023 and December 31, 2022, there were no Warrants and Options Common Stock Warrants Stock warrant transactions for the three months ended March 31, 2023 were as follows: Schedule of Warrant Activity Number of Weighted Average Warrants Exercise Price Warrants outstanding at December 31, 2022 2,337,274 $ 5.30 Granted 9,790,000 0.71 Forfeited/cancelled (78,394 ) 3.40 Exercised - - Warrants outstanding at March 31, 2023 12,048,880 $ 1.60 Warrants exercisable at March 31, 2023 5,158,880 $ 2.39 As of March 31, 2023, all issued and outstanding warrants are fully vested, with the exception of 6.5 390,000 2,900,000 0.0001 Warrants outstanding as of March 31, 2023 are exercisable as follows: Schedule of Warrants Outstanding Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.0001 2,900,000 Indefinite $ 0.0001 2,900,000 $ 0.0001 1.00 1.25 6,890,000 5.2 1.01 - 1.01 3.40 5.50 2,258,880 2.3 5.45 2,258,880 5.45 12,048,880 5,158,880 Common Stock Options Common stock option transactions for the three months ended March 31, 2023 were as follows: Schedule of Options Activity Number of Weighted Average Options Exercise Price Options outstanding at December 31, 2022 1,630,452 $ 2.57 Granted 2,000,000 0.85 Forfeited/cancelled (162,537 ) 2.75 Exercised - - Options outstanding at March 31, 2023 3,467,915 $ 1.56 Options exercisable at March 31, 2023 1,871,141 $ 2.09 The Company is recognizing the corresponding stock compensation expense for options granted to certain consultants, employees, officers and directors based upon their vesting term. On January 27, 2023, the Company granted stock options to employees and members of its board of directors to purchase an aggregate of 2,000,000 0.85 10 years 1.4 Schedule of Stock Granted Assumptions Stock price $ 0.85 Risk-free interest rate 3.62 % Expected volatility 121 % Expected life (in years) 5.3 Expected dividend yield - For the three months ended March 31, 2023, the Company recognized stock compensation expense relating to the vesting of options granted on January 27, 2023 and prior years of $ 507,000 . 46,000 Options outstanding as of March 31, 2023 are exercisable as follows: Schedule of Options Outstanding Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 3.05 151,288 8.7 $ 3.05 151,288 $ 3.05 2.48 1,316,627 9.3 2,48 1,219,853 2.48 0.85 2,000,000 9.8 0.85 500,000 0.85 3,467,915 1,871,141 At March 31, 2023 and 2022, there were 1,596,744 191,285 1.3 511,000 There was no intrinsic value of the outstanding options as of March 31, 2023 as the exercise price of these options was greater than the market price.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Litigation The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters that have arisen under, and are being handled in, the normal course of business. In March 2023, the Company received a demand letter from an attorney representing an alleged holder of a convertible note which alleges that the Company did not deliver shares of common stock that were due on conversion in February 2022. The demand letter contends that the Company is liable for per diem liquidated damages. The Company has denied liability and will defend any such claim vigorously if asserted. On May 13, 2022, the Company made a claim against Michael Handelman, its former Chief Financial Officer, asserting that he misappropriated Company funds and shares of common stock, and failed to file the required SEC reports on Form 3 and Form 4 regarding each acquisition and disposition of the Company’s common stock. The Company seeks monetary damages estimated at $ 370,000 Significant Agreements Research and Development Agreements In June 2017, we entered into a co-development partnership agreement with Altor BioScience Corporation in which we will collaborate exclusively in the clinical development of a novel 161533 (GTB-3550) TriKE ® ® The Company is a party to a Scientific Research Agreement (“SRA”) with the Regents of the University of Minnesota, effective June 16, 2021. This SRA has three major goals: (1) support the Company’s TriKE® product development and GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans; and, (3) investigation of the patient’s native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed here are: (1) creation of IND enabling data for TriKE® constructs in support of our product development and GMP manufacturing efforts; (2) TriKE® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and, (3) gain an increased understanding of changes in the patient’s native NK cell population as a result of TriKE® therapy. Most studies will use TriKE® DNA/amino acid sequences created by us under current UMN/GTB licensing terms. The term of this agreement shall expire on June 30, 2023. The University of Minnesota shall use reasonable efforts to complete the project for a fixed sum of $ 2.1 1.9 The Company has recorded research and development expenses of $ 192,000 192,000 Patent and License Agreements 2016 Exclusive Patent License Agreement The Company is party to an exclusive worldwide license agreement with the Regents of the University of Minnesota, (“UofMN”), to further develop and commercialize cancer therapies using TriKE ® ® ® 200,000 100,000 6% 250,000 5.0 3.1 1.0 250 5.0 500 The Company did no 2021 Patent License Agreement On March 26, 2021, the Company signed an agreement specific to the B7H3 targeted TriKE ® 20,000 5,000 2.5% 5% 250,000 2.0 3.1 1.0 250 5.0 500 The Company did no

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2023
Operating Leases
Operating Leases	Note 8 – Operating Leases On November 19, 2021, the Company entered into a sublease with a third party for 4,500 commencement date of January 1, 2022 and maturing on June 30, 2024 247,000 On February 8, 2022, the Company entered another lease which will end on February 7, 2025. As a result, the Company recognized 13,000 As a result of these lease agreements, the Company recognized ROU asset and liability in the aggregate of $ 260,000 The total rent expense related to these leases reflected on the Company’s Condensed Consolidated Statements of Operations totaled $ 29,000 29,000 Other information related to leases and future minimum lease payments under non-cancellable operating leases were as follows: Schedule of Other Information Related Leases Under Non-Cancellable March 31, 2023 (Unaudited) March 31, 2022 (Unaudited) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 30,445 $ 19,730 Weighted-average remaining lease term (in years): Operating leases 1.5 2.5 Weighted-average discount rate: Operating leases 10 % 10 % Future minimum lease payments under non-cancellable operating leases were as follows (in thousands): Schedule of Future Minimum Lease Payments March 31, 2023 (Unaudited) Within one year $ 123 After one year and within two years 34 After two years and within three years - Thereafter - Total future minimum lease payments 157 Less – Discount (10 ) Lease liability $ 147

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	Note 9 – Subsequent Event On April 28, 2023, the Company issued 552,220 239,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 30, 2023 (the “2022 Annual Report”). The consolidated balance sheet as of December 31, 2022 included herein was derived from the audited consolidated financial statements as of that date. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.
Liquidity	Liquidity The accompanying consolidated financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the three months ended March 31, 2023, the Company recorded a net loss of $ 227,000 , and used cash in operations of $ 2.9 million. As of March 31, 2023, the Company had a cash and short-term investments balance of $ 19.9 million, working capital of $ 15.9 million and stockholders’ equity of $ 13.1 million. Management anticipates that the $ 19.9 million of cash and cash equivalents, and short-term investments are adequate to satisfy the liquidity needs of the Company for at least one year from the date the Company’s condensed consolidated financial statements for the three months ended March 31, 2023 were issued. Historically, the Company has financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not generate sufficient cash flows from investing and financing activities, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs or ability to continue operations.
COVID-19	COVID-19 The global COVID-19 pandemic continues to present uncertainty and unforeseeable risks to GT Biopharma’s operations and business plan. The Company has closely monitored recent developments, including the lifting of COVID-19 safety measures, the spread of new strains or variants of the coronavirus (such as the Delta and Omicron variants), and supply chain and labor shortages. Thus, the full impact of the COVID-19 pandemic on the business and operations remains uncertain and will vary depending on the pandemic’s future impact on the third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. The Company has been following the recommendations of health authorities to minimize exposure risk for its team members and may take further actions that alter our operations, including any required by federal, state or local authorities, or that it determines are in the best interests of its employees and other third parties with whom GT Biopharma does business.
Accounting Estimates	Accounting Estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for services and realization of deferred tax assets. Actual results could differ from those estimates.
Cash Equivalents and Short-Term Investments	Cash Equivalents and Short-Term Investments The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying condensed consolidated financial statements. Total cash equivalents, which consist of money market funds, amounted to approximately $ 1.8 5.5 The Company also invested its excess cash in commercial paper and corporate notes and bonds. Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying condensed consolidated statements of operations. Total short-term investments amounted to approximately $ 17.9 10.8
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. The three levels of the fair value hierarchy are as follows: Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The carrying amount of the Company’s warrant liability of $ 2.9 19,000 The carrying amounts of the Company’s other financial assets and liabilities, such as cash, other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.
Derivatives and Liability-Classified Instruments	Derivatives and Liability-Classified Instruments The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and the guidance provided by the Financial Accounting Standards Board in ASC 480 , Distinguishing Liabilities from Equity (ASC 480) Derivatives and Hedging (ASC 815)
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share-based awards to employees, non-employees and consultants in accordance with the provisions of ASC 718, Compensation-Stock Compensation. Stock-based compensation cost is measured at fair value on the grant date and that fair value is recognized as expense over the requisite service, or vesting period.
Research and Development Costs	Research and Development Costs Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.
Leases	Leases The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments, see Note 7 – Operating Leases for the Company’s lease disclosures.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed using the weighted-average number of common shares outstanding during the period. Common stock issuable is included in our calculation as of the date of the underlying agreement. Diluted loss per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable for the exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Pre-funded warrants are treated as stock equivalents for purposes of calculating net loss per share. These following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities   March 31, 2023 (Unaudited)   March 31, 2022 (Unaudited)   Options to purchase common stock 3,467,915 302,500 Warrants to purchase common stock 9,148,880 2,337,274 Unvested restricted common stock - 681,270 Total anti-dilutive securities  12,616,795   3,321,044
Concentration	Concentration Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $ 250,000 The Company has a significant concentration of expenses incurred and accounts payable from a single vendor, see Note 4– Accounts Payable for further information.
Segments	Segments The Company determined its reporting units in accordance with ASC 280, “Segment Reporting” (“ASC 280”). Management evaluates a reporting unit by first identifying its’ operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated. Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (the “SEC”) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities	These following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive: Schedule of Anti-dilutive Securities   March 31, 2023 (Unaudited)   March 31, 2022 (Unaudited)   Options to purchase common stock 3,467,915 302,500 Warrants to purchase common stock 9,148,880 2,337,274 Unvested restricted common stock - 681,270 Total anti-dilutive securities  12,616,795   3,321,044

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Estimated Fair Value of Financial Instrument	The estimated fair values of financial instruments outstanding were (in thousands): Schedule of Estimated Fair Value of Financial Instrument March 31, 2023 (Unaudited) Unrealized Unrealized Fair Cost Gains Losses Value Short-term investments $ 17,883 $ — $ (29 ) $ 17,854 Total $ 17,883 $ — $ (29 ) $ 17,854 December 31, 2022 Unrealized Unrealized Fair Cost Gains Losses Value Short-term investments $ 10,866 $ — $ (30 ) $ 10,836 Total $ 10,866 $ — $ (30 ) $ 10,836
Schedule of Fair Value Hierarchy Financial Assets	The following table represents the Company’s fair value hierarchy for its financial assets (cash equivalents and investments) (in thousands): Schedule of Fair Value Hierarchy Financial Assets Fair Value Level 1 Level 2 Level 3 March 31, 2023 (Unaudited) Fair Value Level 1 Level 2 Level 3 Money market funds $ 1,837 $ 1,837 $ — $ — Corporate notes and commercial paper 17,854 17,854 — — Total financial assets $ 19,691 $ 19,691 $ — $ — 1 2 3 4 December 31, 2022 Fair Value Level 1 Level 2 Level 3 Money market funds $ 5,505 $ 5,505 $ — $ — Corporate notes and commercial paper 10,836 10,836 — — Total financial assets $ 16,341 $ 16,341 $ — $ —
Schedule of Derivative Liability Transactions	Schedule of Derivative Liability Transactions   March 31, 2023 March 31, 2022   Three Months Ending   March 31, 2023 March 31, 2022   (Unaudited) (Unaudited) Beginning balance $ 19 $ 138 Issuance of warrants at fair value 5,831 — Change in fair value (2,924 ) (18 ) Extinguishment — — Ending balance $ 2,926 $ 120

Accounts Payable (Tables)

Accounts Payable (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accounts Payable	Accounts payable consisted of the following (in thousands): Schedule of Accounts Payable March 31, 2023 (Unaudited) December 31, 2022 Accounts payable to a third-party manufacturer $ 2,114 $ 2,283 Other accounts payable 1,017 857 Total accounts payable $ 3,131 $ 3,140

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2023
Short-Term Debt [Line Items]
Schedule of Derivative Liabilities Assumptions	Schedule of Stock Granted Assumptions Stock price $ 0.85 Risk-free interest rate 3.62 % Expected volatility 121 % Expected life (in years) 5.3 Expected dividend yield -
2023 Warrants [Member]
Short-Term Debt [Line Items]
Schedule of Derivative Liabilities Assumptions	The warrant liabilities for the Common Warrants and the Placement Agents Warrants were valued using a Binomial pricing model with the following assumptions: Schedule of Derivative Liabilities Assumptions (Unaudited) (Unaudited)   Common Warrants and Placement Agents Warrants   At Inception March 31, 2023 (Unaudited) (Unaudited) Stock price $ 1.02 $ 0.55 Risk-free interest rate 3.60 % 3.60 % Expected volatility        121.5%        120.4% Expected average life (in years) 5.0 4.76 Expected dividend yield - - Fair value of warrants (in thousands) $ 5,831 $ 2,919
2020 Warrants [Member]
Short-Term Debt [Line Items]
Schedule of Derivative Liabilities Assumptions	The warrant liabilities for the 2020 warrants were valued using a Binomial pricing model with the following assumptions: Schedule of Derivative Liabilities Assumptions March 31, December 31, 2023 2022 (Unaudited) Stock price $ 0.55 $ 0.89 Risk-free interest rate 4.06 % 4.22 % Expected volatility 106.6 % 109 % Expected life (in years) 2.3 2.6 Expected dividend yield - - Fair value of warrants (in thousands) $ 7,000 $ 19,000

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Class of Warrant or Right [Line Items]
Schedule of Warrants Outstanding	Stock warrant transactions for the three months ended March 31, 2023 were as follows: Schedule of Warrant Activity Number of Weighted Average Warrants Exercise Price Warrants outstanding at December 31, 2022 2,337,274 $ 5.30 Granted 9,790,000 0.71 Forfeited/cancelled (78,394 ) 3.40 Exercised - - Warrants outstanding at March 31, 2023 12,048,880 $ 1.60 Warrants exercisable at March 31, 2023 5,158,880 $ 2.39
Schedule of Options Activity	Common stock option transactions for the three months ended March 31, 2023 were as follows: Schedule of Options Activity Number of Weighted Average Options Exercise Price Options outstanding at December 31, 2022 1,630,452 $ 2.57 Granted 2,000,000 0.85 Forfeited/cancelled (162,537 ) 2.75 Exercised - - Options outstanding at March 31, 2023 3,467,915 $ 1.56 Options exercisable at March 31, 2023 1,871,141 $ 2.09
Schedule of Stock Granted Assumptions	Schedule of Stock Granted Assumptions Stock price $ 0.85 Risk-free interest rate 3.62 % Expected volatility 121 % Expected life (in years) 5.3 Expected dividend yield -
Schedule of Options Outstanding	Options outstanding as of March 31, 2023 are exercisable as follows: Schedule of Options Outstanding Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 3.05 151,288 8.7 $ 3.05 151,288 $ 3.05 2.48 1,316,627 9.3 2,48 1,219,853 2.48 0.85 2,000,000 9.8 0.85 500,000 0.85 3,467,915 1,871,141
Warrants [Member]
Class of Warrant or Right [Line Items]
Schedule of Warrants Outstanding	Warrants outstanding as of March 31, 2023 are exercisable as follows: Schedule of Warrants Outstanding Warrants Outstanding Warrants Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 0.0001 2,900,000 Indefinite $ 0.0001 2,900,000 $ 0.0001 1.00 1.25 6,890,000 5.2 1.01 - 1.01 3.40 5.50 2,258,880 2.3 5.45 2,258,880 5.45 12,048,880 5,158,880

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Operating Leases
Schedule of Other Information Related Leases Under Non-Cancellable	Other information related to leases and future minimum lease payments under non-cancellable operating leases were as follows: Schedule of Other Information Related Leases Under Non-Cancellable March 31, 2023 (Unaudited) March 31, 2022 (Unaudited) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 30,445 $ 19,730 Weighted-average remaining lease term (in years): Operating leases 1.5 2.5 Weighted-average discount rate: Operating leases 10 % 10 %
Schedule of Future Minimum Lease Payments	Future minimum lease payments under non-cancellable operating leases were as follows (in thousands): Schedule of Future Minimum Lease Payments March 31, 2023 (Unaudited) Within one year $ 123 After one year and within two years 34 After two years and within three years - Thereafter - Total future minimum lease payments 157 Less – Discount (10 ) Lease liability $ 147

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	12,616,795	3,321,044
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	3,467,915	302,500
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities	9,148,880	2,337,274
Unvested Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total anti-dilutive securities		681,270

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Net Income (Loss) Attributable to Parent	$ 227,000	$ 5,440,000
Net Cash Provided by (Used in) Operating Activities	2,906,000	5,215,000
Cash on hand and short term investment	19,900,000
Working capital	15,900,000
Equity, Attributable to Parent	13,053,000	17,789,000	$ 11,734,000	$ 21,910,000
Investments and Cash	19,900,000
Cash equivalents	1,800,000		5,500,000
Short-term investments	17,854,000		10,836,000
Derivative liability	2,926,000	$ 120,000	$ 19,000	$ 138,000
FDIC amount	$ 250,000

Schedule of Estimated Fair Valu

Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Cost	$ 17,883	$ 10,866
Unrealized gains
Unrealized losses	(29)	(30)
Fair value	17,854	10,836
Short-Term Investments [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Cost	17,883	10,866
Unrealized gains
Unrealized losses	(29)	(30)
Fair value	$ 17,854	$ 10,836

Schedule of Fair Value Hierarch

Schedule of Fair Value Hierarchy Financial Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	$ 19,691	$ 16,341
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	19,691	16,341
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	1,837	5,505
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	1,837	5,505
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Corporate Notes and Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	17,854	10,836
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	17,854	10,836
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Corporate Notes and Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets

Schedule of Derivative Liabilit

Schedule of Derivative Liability Transactions (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Beginning balance	$ 19,000	$ 138,000
Issuance of warrants at fair value	5,831,000
Change in fair value	(2,924,000)	(18,000)
Extinguishment
Ending balance	$ 2,926,000	$ 120,000

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Derivative liability	$ 2,926,000	$ 19,000	$ 120,000	$ 138,000

Schedule of Accounts Payable (D

Schedule of Accounts Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Accounts payable to a third-party manufacturer	$ 3,131	$ 3,140
Other accounts payable	1,017	857
Total accounts payable	3,131	3,140
Third Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Accounts payable to a third-party manufacturer	2,114	2,283
Total accounts payable	$ 2,114	$ 2,283

Accounts Payable (Details Narra

Accounts Payable (Details Narrative) - USD ($)			3 Months Ended
	Mar. 13, 2023	Mar. 13, 2023	Mar. 31, 2023	Aug. 24, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares. settlement of vendors payable		486,819
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Payable	$ 820,000	$ 820,000	$ 820,000
Shares. settlement of vendors payable	1.3		487,000
Cash			$ 600,000
Stock Issued During Period, Shares, New Issues			486,819
Stock Issued During Period, Value, New Issues			$ 287,000
Gain (Loss) Related to Litigation Settlement			533,000
Service Agreement [Member] | Third Party Manufacturer [Member] | Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts Payable			$ 2,100,000	$ 2,300,000

Schedule of Derivative Liabil_2

Schedule of Derivative Liabilities Assumptions (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Jan. 04, 2023 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ (2,924,000)	$ (18,000)
2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	5,831,000		$ 2,919,000
2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value of warrants	$ 7,000,000		$ 19,000,000
Measurement Input, Share Price [Member] | 2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield | $ / shares	0.55			1.02
Measurement Input, Share Price [Member] | 2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield | $ / shares	0.55		0.89
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	3.62
Measurement Input, Risk Free Interest Rate [Member] | 2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	3.60			3.60
Measurement Input, Risk Free Interest Rate [Member] | 2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	4.06		4.22
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	121
Measurement Input, Price Volatility [Member] | 2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	120.04			121.05
Measurement Input, Price Volatility [Member] | 2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	106.6		109
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (in years)	5 years 3 months 18 days
Measurement Input, Expected Term [Member] | 2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (in years)	4 years 9 months 3 days		5 years
Measurement Input, Expected Term [Member] | 2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (in years)	2 years 7 months 6 days		2 years 3 months 18 days
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
Measurement Input, Expected Dividend Rate [Member] | 2023 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield
Measurement Input, Expected Dividend Rate [Member] | 2020 Warrants [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield

Warrant Liability (Details Narr

Warrant Liability (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jan. 04, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair value	$ (2,924,000)	$ (18,000)
Derivative liability	2,926,000	120,000		$ 19,000	$ 138,000
Fair value adjustment of warrants	$ 2,924,000	$ 18,000
Common Warrants [Member] | Pre Funded Warrants [Member]
Placement agent warrants to purchase up			6,500,000
Placement Agent Warrant [Member] | Maximum [Member]
Placement agent warrants to purchase up			390,000
Warrant [Member]
Fair value of volatility amount	100%
Fair value	$ 5,800,000
Derivative liability	2,900,000
Fair value adjustment of warrants	$ (5,800,000)

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Equity [Abstract]
Warrants outstanding, beginning balance | shares	2,337,274
Weighted average exercise price, beginning balance | $ / shares	$ 5.30
Number of warrants, granted | shares	9,790,000
Weighted average exercise price, granted | $ / shares	$ 0.71
Number of warrants, forfeited | shares	(78,394)
Weighted average exercise price, forfeited | $ / shares	$ 3.40
Number of warrants, exercised | shares
Weighted average exercise price, exercised | $ / shares
Warrants outstanding, beginning balance | shares	12,048,880
Weighted average exercise price, beginning balance | $ / shares	$ 1.60
Warrants exercisable, ending balance | shares	5,158,880
Exercisable, ending balance | $ / shares	$ 2.39

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	1 Months Ended	3 Months Ended
	Jan. 27, 2023	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Warrants outstanding		12,048,880	2,337,274
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 1.60	$ 5.30
Warrants exercisable	1,400,000	1,871,141
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 2.39
Remaining contractual life years	10 years
Range One [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		3.05
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 3.05
Warrants exercisable		151,288
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 3.05
Remaining contractual life years		8 years 8 months 12 days
Range Two [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		$ 2.48
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 2.48
Warrants exercisable		1,219,853
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 2.48
Remaining contractual life years		9 years 3 months 18 days
Range Three [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		$ 0.85
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 0.85
Warrants exercisable		500,000
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 0.85
Remaining contractual life years		9 years 9 months 18 days
Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding		12,048,880
Warrants exercisable		5,158,880
Warrants [Member] | Range One [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		$ 0.0001
Warrants outstanding		2,900,000
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 0.0001
Warrants exercisable		2,900,000
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 0.0001
Warrants [Member] | Range Two [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		$ 1.25
Warrants outstanding		6,890,000
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 1.01
Warrants exercisable
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 1.01
Range of lower excercise price, per share		$ 1
Remaining contractual life years		5 years 2 months 12 days
Warrants [Member] | Range Three [Member]
Class of Warrant or Right [Line Items]
Range of upper excercise price, per share		$ 5.50
Warrants outstanding		2,258,880
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 5.45
Warrants exercisable		2,258,880
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 5.45
Range of lower excercise price, per share		$ 3.40
Remaining contractual life years		2 years 3 months 18 days

Schedule of Options Activity (D

Schedule of Options Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Equity [Abstract]
Number of options outstanding, beginning | shares	1,630,452
Weighted-Average Exercise Price, Beginning | $ / shares	$ 2.57
Number of options, Granted | shares	2,000,000
Weighted-Average Exercise Price, Granted | $ / shares	$ 0.85
Number of options, Forfeited | shares	(162,537)
Weighted-Average Exercise Price, Forfeited | $ / shares	$ 2.75
Number of options, Exercised | shares
Weighted-Average Exercise Price, Exercised | $ / shares
Number of options outstanding, ending | shares	3,467,915
Weighted-Average Exercise Price, Beginning | $ / shares	$ 1.56
Number of options outstanding, exercisable | shares	1,871,141
Weighted-Average Exercise Price, Ending | $ / shares	$ 2.09

Schedule of Stock Granted Assum

Schedule of Stock Granted Assumptions (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price	$ 0.85
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	3.62
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield	121
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected life (in years)	5 years 3 months 18 days
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected dividend yield

Schedule of Options Outstanding

Schedule of Options Outstanding (Details) - $ / shares	1 Months Ended	3 Months Ended
	Jan. 27, 2023	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding		3,467,915	1,630,452
Options outstanding remaining contractual life years	10 years
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 1.60	$ 5.30
Warrants exercisable	1,400,000	1,871,141
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 2.39
Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of upper excercise price, per share		$ 3.05
Options outstanding		151,288
Options outstanding remaining contractual life years		8 years 8 months 12 days
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 3.05
Warrants exercisable		151,288
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 3.05
Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of upper excercise price, per share		$ 2.48
Options outstanding		1,316,627
Options outstanding remaining contractual life years		9 years 3 months 18 days
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 2.48
Warrants exercisable		1,219,853
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 2.48
Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of upper excercise price, per share		$ 0.85
Options outstanding		2,000,000
Options outstanding remaining contractual life years		9 years 9 months 18 days
Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price		$ 0.85
Warrants exercisable		500,000
Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price		$ 0.85

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 13, 2023	Mar. 13, 2023	Jan. 04, 2023	Feb. 16, 2021	Jan. 27, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized						250,000,000			250,000,000
Common stock, par value						$ 0.001			$ 0.001
Preferred stock, shares authorized						15,000,000			15,000,000
Preferred stock, par value						$ 0.01			$ 0.01
Cash Acquired from Acquisition			$ 6,500,000
Common Stock, Shares, Issued						36,882,724			32,722,452
Fair value						$ (2,924,000)	$ (18,000)
Number of shares cancelled in common stock							290,999
Shares issued, value						315,000	$ 872,000
Common stock issued		486,819
Common stock issued, value		$ 287,000				$ 287,000
Gain on fair value of debt		533,000
Exercise price						$ 0.85
Shares granted					$ 2,000,000
Price per share					$ 0.85
Expiry period					10 years
Share vested value					1,400,000	1,871,141
Unvested options						1,596,744	191,285
Stock compensation expense						$ 1,300,000	$ 511,000
Equity Option [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options granted						$ 507,000	$ 46,000
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, par value						$ 0.01			$ 0.01
Preferred stock, shares outstanding						96,230			96,230
Preferred stock, shares issued						96,230			96,230
Series K Preferred Stocks [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, par value				$ 0.01
Preferred stock shares designated				115,000
Convertible shares issuable				100
Series K Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares outstanding						0			0
Board Of Directors Employees And Consultants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued						73,454	247,429
Shares issued, value						$ 315,000	$ 1,300,000
Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants purchase of common stock						6,500,000
Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants purchase of common stock						390,000
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Noninterest Expense Offering Cost			$ 232,000
Purchase Agreement [Member] | Institutional Investor [Member] | Pre Funded Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.0001
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized						250,000,000
Preferred stock shares designated						486,819
Debt converted amount				$ 38,800,000
Converted conversion of common stock				11,413,322				11,086,024
Shares issued, value						$ 287,000
Shares issued						73,000	163,000
Shares issued, value
Common stock issued	1.3					487,000
Common stock issued, value
Accounts payable	$ 820,000	$ 820,000				820,000
Common Stock [Member] | Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common Stock, Shares, Issued			3,600,000
Shares Issued, Price Per Share			$ 0.001
Preferred stock shares designated			6,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.25
Prefunded Warrant [Member] | Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants purchase of common stock			2,900,000
Placement Agent Warrant [Member] | Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock shares designated			390,000
Common Warrants [Member] | Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Issued, Price Per Share			$ 1
Common Warrant and Placement Agent Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value			$ 5,800,000
Common Stock Issuable [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock shares designated								327,298
Shares issued, value							$ 1,100,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value						$ 5,800,000
Warrants outstanding						2,900,000
Exercise price						$ 0.0001

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)			3 Months Ended
	May 13, 2022	Mar. 26, 2021	Mar. 31, 2023	Mar. 31, 2022
Loss Contingencies [Line Items]
Monetary damages estimated amount	$ 370,000
Project fee			$ 2,100,000
Research and development expense			1,900,000
Research and development expense			1,650,000	$ 2,087,000
Scientific Research Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense			192,000	$ 192,000
2016 Patent Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense			0
Proceeds from upfront amount			200,000
Maintenance fee			100,000
Performance milestone payments			3,100,000
Sales milestone payments			1,000,000
Gross sales			250,000,000
Sales revenue			5,000,000
Cumulative gross sales			$ 500,000,000
2016 Patent Exclusive License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Net sales percentage			6%
Annual royalty payments			$ 5,000,000
2016 Patent Exclusive License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Annual royalty payments			250,000
2021 Patent License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense			$ 0
Maintenance fee		$ 2,000,000
Annual royalty payments		250,000
Performance milestone payments		3,100,000
Sales milestone payments		1,000,000
Gross sales		250,000,000
Sales revenue		5,000,000
Cumulative gross sales		500,000,000
Upfront license fee		20,000
License maintenance fee, receivable		$ 5,000
2021 Patent License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Net sales percentage		5%
2021 Patent License Agreement [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Net sales percentage		2.50%

Schedule of Other Information R

Schedule of Other Information Related Leases Under Non-Cancellable (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Leases
Operating cash flows from operating leases	$ 30,445	$ 19,730
Weighted average remaining lease term operating leases	1 year 6 months	2 years 6 months
Weighted average discount rate operating leases	10%	10%

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Operating Leases
Within one year	$ 123
After one year and within two years	34
After two years and within three years
Thereafter
Total future minimum lease payments	157
Less – Discount	(10)
Lease liability	$ 147

Operating Leases (Details Narra

Operating Leases (Details Narrative)		3 Months Ended
	Nov. 19, 2021 USD ($) ft²	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Feb. 08, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Right of use asset		$ 140,000		$ 165,000
Right of use liability		157,000
Rent expense		29,000	$ 29,000
Lease Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	4,500
Commencement date	commencement date of January 1, 2022 and maturing on June 30, 2024
Right of use asset	$ 247,000	260,000			$ 13,000
Right of use liability		$ 260,000			$ 13,000

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - Common Stock [Member] - USD ($)		3 Months Ended
	Apr. 28, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Common stock, shares issued		486,819
Common stock, fair value		$ 287,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares issued	552,220
Common stock, fair value	$ 239,000